However, the exploration of the antitumor efficacy of HER2 antibodies and tyrosine kinase inhibitors (TKIs) in HER2-positive urothelial carcinoma (UC) has encountered dilemmas (15, 16). Here, ERBB2 is linked to urothelial carcinoma.